Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 14/20 | 0.73 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.47 |
| ▸ | PLK1 | P53350 | 2/20 | 0.45 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.45 |
| ▸ | PLK2 | Q9NYY3 | 2/20 | 0.45 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13494643 | 0.87 | DYRK1A (0.57) | DYRK1APLA2G2AHTR2AHTR2C | |
| SCHEMBL27899833 | 0.86 | DYRK1A (0.55) | DYRK1ASRCHASPIN | |
| SCHEMBL12070349 | 0.84 | DYRK1A (1.00) | DYRK1APLK1PLK3PLK2HASPIN | |
| SCHEMBL27908712 | 0.84 | DYRK1A (0.67) | DYRK1AMCL1 | |
| SCHEMBL2215202 | 0.83 | DYRK1A (0.81) | DYRK1AHASPINACHEMAOAHTR2A | |
| SCHEMBL27921175 | 0.83 | DYRK1A (0.67) | DYRK1AHASPINACHEMAOAHTR2A | |
| SCHEMBL27939720 | 0.80 | DYRK1A (0.50) | DYRK1AHASPINACHEMAOAHTR2A | |
| SCHEMBL8852076 | 0.79 | DYRK1A (0.70) | DYRK1AHASPIN | |
| SCHEMBL30939988 | 0.78 | DYRK1A (0.71) | DYRK1AHASPINHTR2AHTR2C | |
| SCHEMBL16123659 | 0.78 | DYRK1A (0.71) | DYRK1AHASPINHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9168247-B2 | Beta carboline derivatives useful in the treatment of proliferative disorders | FACULTES UNIVERSITAIRES NOTRE DAME DE LA PAIX (BE) | 2015-10-27 | — | — | US | disclosed |
| US-9168247-B2 | Beta carboline derivatives useful in the treatment of proliferative disorders | FACULTES UNIVERSITAIRES NOTRE DAME DE LA PAIX (BE) | 2015-10-27 | — | — | US | disclosed |
| US-9168247-B2 | Beta carboline derivatives useful in the treatment of proliferative disorders | FACULTES UNIVERSITAIRES NOTRE DAME DE LA PAIX (BE) | 2015-10-27 | — | — | US | disclosed |
| US-20140005220-A9 | BETA CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2014-01-02 | — | — | US | disclosed |
| US-20130116273-A1 | BETA CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2013-05-09 | — | — | US | disclosed |
| US-20130116273-A1 | BETA CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2013-05-09 | — | — | US | disclosed |
| US-20130116273-A1 | BETA CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2013-05-09 | — | — | US | disclosed |
| WO-2011161256-A1 | BETA CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | FACULTES UNIVERSITAIRES NOTRE DAME DE LA PAIX (BE) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005220-A9 | BETA CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CCNI, CCNA1, BRCA1 | DYRK1A 2151/4885SRC 3918/4885PLA2G2A 4165/4885 |
| US-20130116273-A1 | BETA CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CCNI, CCNA1, BRCA1 | DYRK1A 2151/4885SRC 3918/4885PLA2G2A 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.